|
DZ2376A1
(fr)
*
|
1996-12-19 |
2002-12-28 |
Smithkline Beecham Plc |
Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
|
|
IL133870A0
(en)
*
|
1997-07-11 |
2001-04-30 |
Smithkline Beecham Plc |
Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
|
|
AU759255B2
(en)
|
1998-01-29 |
2003-04-10 |
Amgen, Inc. |
PPAR-gamma modulators
|
|
GB9803411D0
(en)
*
|
1998-02-18 |
1998-04-15 |
Smithkline Beecham Plc |
Novel compounds
|
|
US6194410B1
(en)
*
|
1998-03-11 |
2001-02-27 |
Hoffman-La Roche Inc. |
Pyrazolopyrimidine and pyrazolines and process for preparation thereof
|
|
GB9810671D0
(en)
*
|
1998-05-18 |
1998-07-15 |
Pfizer Ltd |
Anti-pruritic agents
|
|
GB9818916D0
(en)
*
|
1998-08-28 |
1998-10-21 |
Smithkline Beecham Plc |
Use
|
|
GB9818914D0
(en)
*
|
1998-08-28 |
1998-10-21 |
Smithkline Beecham Plc |
Use
|
|
GB9820113D0
(en)
|
1998-09-15 |
1998-11-11 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
US7041691B1
(en)
|
1999-06-30 |
2006-05-09 |
Amgen Inc. |
Compounds for the modulation of PPARγ activity
|
|
GB9926302D0
(en)
*
|
1999-11-05 |
2000-01-12 |
Smithkline Beecham Plc |
Novel compounds
|
|
CA2394603A1
(en)
*
|
1999-12-21 |
2001-06-28 |
Dashyant Dhanak |
Urotensin-ii receptor antagonists
|
|
SE9904723D0
(sv)
*
|
1999-12-22 |
1999-12-22 |
Carlsson A Research Ab |
New modulators of dopamine neurotransmission II
|
|
SE0001899D0
(sv)
|
2000-05-22 |
2000-05-22 |
Pharmacia & Upjohn Ab |
New compounds
|
|
US20030171399A1
(en)
|
2000-06-28 |
2003-09-11 |
Tularik Inc. |
Quinolinyl and benzothiazolyl modulators
|
|
SE0002739D0
(sv)
*
|
2000-07-21 |
2000-07-21 |
Pharmacia & Upjohn Ab |
New use
|
|
SE0002754D0
(sv)
*
|
2000-07-21 |
2000-07-21 |
Pharmacia & Upjohn Ab |
New pharmaceutical combination formulation and method of treatment with the combination
|
|
US6399617B1
(en)
|
2000-07-21 |
2002-06-04 |
Biovitrum Ab |
Use
|
|
US6818639B2
(en)
|
2000-07-21 |
2004-11-16 |
Biovitrum Ab |
Pharmaceutical combination formulation and method of treatment with the combination
|
|
EP1325920B1
(en)
*
|
2000-09-18 |
2010-08-25 |
TOA Eiyo Ltd. |
N-substituted benzothiophenesulfonamide derivatives
|
|
US7071220B2
(en)
|
2000-09-18 |
2006-07-04 |
Toa Eiyo Ltd. |
N-substituted benzothiophenesulfonamide derivatives
|
|
US7034029B2
(en)
|
2000-11-02 |
2006-04-25 |
Wyeth |
1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
|
|
US6849644B2
(en)
|
2000-11-21 |
2005-02-01 |
Smithkline Beecham P.L.C. |
Isoquinoline derivatives useful in the treatment of CNS disorders
|
|
CN1289072C
(zh)
|
2000-12-22 |
2006-12-13 |
石原产业株式会社 |
苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂
|
|
JP2004534017A
(ja)
*
|
2001-04-27 |
2004-11-11 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ｂａｃｅのインヒビター
|
|
WO2002089740A2
(en)
*
|
2001-05-07 |
2002-11-14 |
Smithkline Beecham Corporation |
Sulfonamides
|
|
US6743796B2
(en)
*
|
2001-05-07 |
2004-06-01 |
Wyeth |
Piperazinyl-isatins
|
|
AR033879A1
(es)
*
|
2001-05-07 |
2004-01-07 |
Smithkline Beecham Corp |
Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto
|
|
EP1387679A4
(en)
*
|
2001-05-07 |
2004-08-11 |
Smithkline Beecham Corp |
SULPHONAMIDES
|
|
US6849635B2
(en)
*
|
2001-05-07 |
2005-02-01 |
Smithkline Beecham Corporation |
Sulfonamides
|
|
WO2002090337A1
(en)
*
|
2001-05-07 |
2002-11-14 |
Smithkline Beecham Corporation |
Sulfonamides
|
|
GB0111186D0
(en)
*
|
2001-05-08 |
2001-06-27 |
Smithkline Beecham Plc |
Novel compounds
|
|
RS88803A
(sr)
*
|
2001-05-11 |
2007-02-05 |
Biovitrum Ab., |
Nova jedinjenja arilsulfonamida za lečenje gojaznosti, dijabetesa tipa ii i poremećaja cns
|
|
US7718650B2
(en)
|
2001-05-11 |
2010-05-18 |
Biovitrum Ab |
Aryl sulfonamide compounds for treating obesity
|
|
MXPA03010232A
(es)
|
2001-05-11 |
2004-03-16 |
Biovitrum Ab |
Compuestos de arilsulfonamida, para el tratamiento de la obesidad, de la diabetes tipo ii y de trastornos del sistema nervioso central.
|
|
RU2294932C2
(ru)
|
2001-06-07 |
2007-03-10 |
Ф.Хоффманн-Ля Рош Аг |
Новые производные индола со сродством к рецептору 5-ht6
|
|
CN100457726C
(zh)
|
2001-06-11 |
2009-02-04 |
比奥维特罗姆股份公开公司 |
取代的磺酰胺化合物、其制备方法及其作为治疗cns疾病、肥胖和ⅱ型糖尿病的药物的应用
|
|
MXPA03011638A
(es)
|
2001-06-15 |
2004-04-02 |
Hoffmann La Roche |
Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
|
|
US6727264B1
(en)
*
|
2001-07-05 |
2004-04-27 |
Synaptic Pharmaceutical Corporation |
Substituted anilinic piperidines as MCH selective antagonists
|
|
US20040242589A1
(en)
*
|
2001-08-07 |
2004-12-02 |
Bromidge Steven Mark |
3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
|
|
RU2268884C2
(ru)
|
2001-08-10 |
2006-01-27 |
Ф.Хоффманн-Ля Рош Аг |
Арилсульфонильные производные, обладающие сродством к рецептору 5-ht6, и способ их получения
|
|
TWI325317B
(en)
*
|
2001-09-05 |
2010-06-01 |
Eisai R&D Man Co Ltd |
Appetite-stimulating agents and remedies for anorexia
|
|
SE0103644D0
(sv)
*
|
2001-11-01 |
2001-11-01 |
Astrazeneca Ab |
Therapeutic isoquinoline compounds
|
|
EP1450806B1
(en)
*
|
2001-11-09 |
2009-04-29 |
Biovitrum AB (publ) |
Use of sulfonamide derivatives in the treatment of obesity or for the reduction of food intake
|
|
RS44204A
(sr)
|
2001-11-22 |
2007-06-04 |
Biovitrum Ab., |
Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
|
|
EA200400707A1
(ru)
|
2001-11-22 |
2004-10-28 |
Биовитрум Аб |
Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
|
|
JP2005516903A
(ja)
*
|
2001-11-30 |
2005-06-09 |
エフ．ホフマン−ラ ロシュ アーゲー |
喘息の処置におけるｃｃｒ−３受容体拮抗物質として使用するためのピペラジン誘導体
|
|
PL372390A1
(en)
*
|
2002-02-05 |
2005-07-25 |
Novo Nordisk A/S |
Novel aryl- and heteroarylpiperazines
|
|
WO2003066056A1
(en)
*
|
2002-02-05 |
2003-08-14 |
Glaxo Group Limited |
Method of promoting neuronal growth
|
|
WO2003068732A2
(en)
*
|
2002-02-13 |
2003-08-21 |
Glaxo Group Limited |
Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor liga ds
|
|
US20050090485A1
(en)
*
|
2002-02-13 |
2005-04-28 |
Bromidge Steven M. |
7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders
|
|
PL371344A1
(en)
*
|
2002-02-13 |
2005-06-13 |
Glaxo Group Limited |
Benzenesulfonamide derivatives as antipsychotic agents
|
|
AR039127A1
(es)
|
2002-03-27 |
2005-02-09 |
Glaxo Group Ltd |
Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
|
|
US20040142948A1
(en)
*
|
2002-05-07 |
2004-07-22 |
Dashyant Dhanak |
Sulfonamides
|
|
UA76877C2
(uk)
*
|
2002-05-13 |
2006-09-15 |
Ф.Хоффманн-Ля Рош Аг |
Похідні бензоксазину як 5-нт6 модулятори і їх застосування
|
|
CN1662521A
(zh)
*
|
2002-06-20 |
2005-08-31 |
比奥维特罗姆股份公司 |
可用于治疗肥胖、ii型糖尿病和cns障碍的新化合物
|
|
JP4754821B2
(ja)
*
|
2002-06-20 |
2011-08-24 |
プロキシマゲン・リミテッド |
肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
|
|
EP1897881A3
(en)
|
2002-06-20 |
2009-03-18 |
Biovitrum AB (publ) |
Compounds useful for the treatment of obesity, type II diabetes and CNS disorders
|
|
JP2006505559A
(ja)
|
2002-10-18 |
2006-02-16 |
エフ．ホフマン−ラ ロシュ アーゲー |
５−ｈｔ６受容体親和性を持つ４−ピペラジニルベンゼンスルホニルインドール
|
|
AU2003295408A1
(en)
*
|
2002-11-06 |
2004-06-03 |
Smithkline Beecham Corporation |
Sulfonamides
|
|
WO2004043369A2
(en)
*
|
2002-11-06 |
2004-05-27 |
Smithkline Beecham Corporation |
Sulfonamides
|
|
RS20050532A
(sr)
|
2003-01-14 |
2007-12-31 |
Arena Pharmaceuticals Inc., |
Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
|
|
US7153858B2
(en)
|
2003-01-31 |
2006-12-26 |
Epix Delaware, Inc. |
Arylpiperazinyl compounds
|
|
WO2004072087A2
(de)
*
|
2003-02-13 |
2004-08-26 |
Lanxess Deutschland Gmbh |
Metallkomplexe als lichtabsorbierende verbindungen in der informationsschicht von optischen datenträgern
|
|
WO2004073634A2
(en)
*
|
2003-02-20 |
2004-09-02 |
Encysive Pharmaceuticals Inc. |
Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists
|
|
TWI289141B
(en)
*
|
2003-03-11 |
2007-11-01 |
Hoffmann La Roche F. Ag. |
Quinolinone derivatives and uses thereof
|
|
US7262197B2
(en)
*
|
2003-03-31 |
2007-08-28 |
Janssen Pharmaceutica, N.V |
Phospholipase C inhibitors for use in treating inflammatory disorders
|
|
US6946466B2
(en)
*
|
2003-04-10 |
2005-09-20 |
Schering Ag |
Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
|
|
US20040204422A1
(en)
*
|
2003-04-14 |
2004-10-14 |
Abbott Gmbh & Co. Kg. |
N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
|
|
NZ544331A
(en)
|
2003-07-22 |
2010-03-26 |
Arena Pharm Inc |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
|
|
GB0320320D0
(en)
*
|
2003-08-29 |
2003-10-01 |
Glaxo Group Ltd |
Novel compounds
|
|
US7223761B2
(en)
|
2003-10-03 |
2007-05-29 |
Amgen Inc. |
Salts and polymorphs of a potent antidiabetic compound
|
|
KR20060127886A
(ko)
*
|
2003-12-19 |
2006-12-13 |
바이오비트럼 에이비 |
5-ｈｔ6 수용체-관련 장애의 예방 및 치료에 사용될 수있는, 신규한 벤조퓨란 유도체
|
|
SE0303480D0
(sv)
|
2003-12-19 |
2003-12-19 |
Biovitrum Ab |
Benzofuranes
|
|
WO2006010629A1
(en)
|
2004-07-28 |
2006-02-02 |
Glaxo Group Limited |
Piperazine derivatives useful for the treatment of gastrointestinal disorders
|
|
EP1799306B1
(en)
*
|
2004-09-30 |
2011-02-23 |
F. Hoffmann-La Roche AG |
Compositions and methods for treating cognitive disorders
|
|
JP4754570B2
(ja)
|
2004-10-14 |
2011-08-24 |
アボット ゲーエムベーハー ウント カンパニー カーゲー |
ドーパミンｄ３受容体の調節に応答する障害の治療に好適なアザビシクロヘプチル化合物
|
|
US7851463B2
(en)
|
2004-10-14 |
2010-12-14 |
Abbott Gmbh & Co. Kg |
Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
|
|
WO2006062481A1
(en)
*
|
2004-12-09 |
2006-06-15 |
Biovitrum Ab |
New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
|
|
EP1676841A1
(en)
*
|
2004-12-30 |
2006-07-05 |
Esteve Laboratorios Dr. Esteve S.A. |
Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments
|
|
WO2006075808A1
(en)
*
|
2005-01-12 |
2006-07-20 |
Inje University |
Pharmaceutical composition comprising a p25/cdk5 inhibitor for preventing or treating a neurodegenerative disease
|
|
CN103110635A
(zh)
|
2005-07-04 |
2013-05-22 |
海波因特制药有限责任公司 |
组胺h3受体拮抗剂
|
|
US7998981B2
(en)
|
2005-08-12 |
2011-08-16 |
Suven Life Sciences Limited |
Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands
|
|
US7923566B2
(en)
|
2005-08-16 |
2011-04-12 |
Suven Life Sciences Limited |
Alternative process for the preparation of losartan
|
|
US20100048713A1
(en)
*
|
2006-01-06 |
2010-02-25 |
Aarhus Universitet |
Compounds acting on the serotonin transporter
|
|
WO2007113202A1
(en)
|
2006-03-31 |
2007-10-11 |
Glaxo Group Limited |
Piperazine derivatives as growth hormone secretagogue (ghs) receptor agonists
|
|
TW200808762A
(en)
|
2006-04-19 |
2008-02-16 |
Abbott Gmbh & Co Kg |
Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor
|
|
TW200812961A
(en)
|
2006-04-19 |
2008-03-16 |
Abbott Gmbh & Co Kg |
Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor
|
|
CA2653062A1
(en)
|
2006-05-23 |
2007-11-29 |
Transtech Pharma, Inc. |
6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament
|
|
ATE538116T1
(de)
|
2006-05-29 |
2012-01-15 |
High Point Pharmaceuticals Llc |
3-(1,3-benyodioxol-5-yl)-6- (4- cyclopropylpiperazin-1-yl)-pyridazin, dessen salze und solvate und dessen verwendung als histamin-h3-rezeptorantagonist
|
|
EP2086329B1
(en)
|
2006-10-26 |
2014-07-23 |
The Arizona Board of Regents on behalf of the University of Arizona |
Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
|
|
CN101553467B
(zh)
|
2007-01-08 |
2011-12-07 |
苏文生命科学有限公司 |
5-(杂环基)烷基-n-(芳基磺酰基)吲哚化合物及其作为5-ht6配体的用途
|
|
JP5208963B2
(ja)
*
|
2007-01-10 |
2013-06-12 |
エフ．ホフマン−ラ ロシュ アーゲー |
キマーゼ阻害剤としてのスルホンアミド誘導体
|
|
AU2008231789A1
(en)
|
2007-03-23 |
2008-10-02 |
Abbott Gmbh & Co. Kg |
Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
|
|
AU2008246947B2
(en)
|
2007-05-03 |
2011-03-31 |
Suven Life Sciences Limited |
Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT6 ligands
|
|
EP2014656A3
(en)
|
2007-06-11 |
2011-08-24 |
High Point Pharmaceuticals, LLC |
New heteocyclic h3 antagonists
|
|
DE602007012683D1
(de)
*
|
2007-07-19 |
2011-04-07 |
Esteve Labor Dr |
Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente
|
|
CA2703157C
(en)
|
2007-10-26 |
2013-02-05 |
Suven Life Sciences Limited |
Amino arylsulfonamide compounds and their use as 5-ht6 ligands
|
|
PA8802201A1
(es)
*
|
2007-11-02 |
2009-06-23 |
Abbott Gmbh & Co Kg |
Compuestos de bencensulfonalida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6
|
|
EP2254564A1
(en)
|
2007-12-12 |
2010-12-01 |
Glaxo Group Limited |
Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
|
|
WO2009123714A2
(en)
|
2008-04-02 |
2009-10-08 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
|
US20110034565A1
(en)
|
2008-04-18 |
2011-02-10 |
University College Dublin, National University Of Ireland, Dublin |
Psycho-pharmaceuticals
|
|
UA103319C2
(en)
|
2008-05-06 |
2013-10-10 |
Глаксосмитклайн Ллк |
Thiazole- and oxazole-benzene sulfonamide compounds
|
|
EA201001847A1
(ru)
*
|
2008-06-11 |
2011-08-30 |
Айрм Ллк |
Соединения и композиции, применяемые для лечения малярии
|
|
MX2011002884A
(es)
|
2008-09-17 |
2011-04-21 |
Suven Life Sciences Ltd |
Compuestos de aril-sulfonamida-amina y su uso como ligandos de 5-ht6.
|
|
US8318725B2
(en)
|
2008-09-17 |
2012-11-27 |
Suven Life Sciences Limited |
Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
|
|
US9126946B2
(en)
|
2008-10-28 |
2015-09-08 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
|
|
UA100192C2
(en)
|
2008-11-11 |
2012-11-26 |
УАЙТ ЭлЭлСи |
1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
|
|
KR101073703B1
(ko)
|
2009-04-07 |
2011-10-14 |
한국화학연구원 |
피페라진 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계 질환의 예방 또는 치료용 약학적 조성물
|
|
MX2011011515A
(es)
|
2009-04-30 |
2012-01-30 |
Abbott Gmbh & Co Kg |
Compuestos de bencensulfonanilida adecuados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6.
|
|
US8343959B2
(en)
|
2009-04-30 |
2013-01-01 |
Abbott Gmbh & Co. Kg |
N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
|
|
CA2759482A1
(en)
|
2009-04-30 |
2010-11-04 |
Abbott Gmbh & Co. Kg |
N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
|
|
CA2759491A1
(en)
|
2009-04-30 |
2010-11-04 |
Abbott Gmbh & Co. Kg. |
Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
|
|
MX2012007783A
(es)
|
2010-01-05 |
2012-10-03 |
Suven Life Sciences Ltd |
Compuestos sulfona que actuan como ligandos del receptor 5-ht6.
|
|
CN103221410B
(zh)
|
2010-09-22 |
2017-09-15 |
艾尼纳制药公司 |
Gpr119受体调节剂和对与其相关的障碍的治疗
|
|
WO2012059431A1
(en)
|
2010-11-01 |
2012-05-10 |
Abbott Gmbh & Co. Kg |
Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
|
|
WO2012059432A1
(en)
|
2010-11-01 |
2012-05-10 |
Abbott Gmbh & Co. Kg |
N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
|
|
ES2413911B1
(es)
*
|
2011-12-15 |
2014-05-14 |
Universidad De Zaragoza |
Agente inhibidor de la agregación del peptido beta amiloide.
|
|
KR20140135835A
(ko)
|
2012-03-20 |
2014-11-26 |
아다메드 에스피. 제트 오.오. |
Cns 질환의 치료를 위한 벤질아민의 설폰아미드 유도체
|
|
PT2970205T
(pt)
|
2013-03-14 |
2019-08-26 |
Tolero Pharmaceuticals Inc |
Inibidores da jak2 e da alk2 e métodos para a sua utilização
|
|
PL3027613T3
(pl)
|
2013-07-25 |
2018-10-31 |
Uniwersytet Jagielloński |
Pochodne pirolochinoliny jako antagonisty 5-HT6, sposób wytwarzania i ich zastosowanie
|
|
EP3134392B1
(en)
|
2014-04-19 |
2019-01-02 |
Sunshine Lake Pharma Co., Ltd. |
Sulfonamide derivatives and pharmaceutical applications thereof
|
|
CN105367472B
(zh)
*
|
2014-08-12 |
2020-04-21 |
广东东阳光药业有限公司 |
吲哚啉类衍生物及其在药物上的应用
|
|
CN105367473B
(zh)
*
|
2014-08-12 |
2020-02-11 |
广东东阳光药业有限公司 |
吲哚啉类衍生物及其在药物上的应用
|
|
CA3002540C
(en)
|
2015-01-06 |
2023-11-07 |
Arena Pharmaceuticals, Inc. |
Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
|
|
JP2018516992A
(ja)
|
2015-06-12 |
2018-06-28 |
アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ |
レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
|
|
JP6838744B2
(ja)
|
2015-06-22 |
2021-03-03 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
|
|
CN108472285A
(zh)
|
2015-07-15 |
2018-08-31 |
阿速万科学有限责任公司 |
用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
|
|
CN108926565A
(zh)
*
|
2017-05-26 |
2018-12-04 |
中国科学院上海生命科学研究院 |
五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用
|
|
WO2019180176A1
(en)
|
2018-03-21 |
2019-09-26 |
Spherium Biomed, S.L. |
Composition for the treatment of schizophrenia and/or psychosis
|
|
JP7397011B2
(ja)
|
2018-06-06 |
2023-12-12 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
Ｓ１ｐ１受容体に関連する状態を治療する方法
|
|
KR20210038906A
(ko)
|
2018-07-26 |
2021-04-08 |
스미토모 다이니폰 파마 온콜로지, 인크. |
비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
|